BioRegenx Statistics
Total Valuation
BioRegenx has a market cap or net worth of 8.99 million. The enterprise value is 11.11 million.
| Market Cap | 8.99M |
| Enterprise Value | 11.11M |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioRegenx has 971.58 million shares outstanding. The number of shares has increased by 0.32% in one year.
| Current Share Class | 971.58M |
| Shares Outstanding | 971.58M |
| Shares Change (YoY) | +0.32% |
| Shares Change (QoQ) | +0.78% |
| Owned by Insiders (%) | 12.33% |
| Owned by Institutions (%) | n/a |
| Float | 258.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.09 |
| PB Ratio | -1.98 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 476.79 |
| P/OCF Ratio | 322.05 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.52 |
| EV / Sales | 6.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 589.24 |
Financial Position
The company has a current ratio of 0.05
| Current Ratio | 0.05 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 114.88 |
| Interest Coverage | -1.24 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -57.36% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 10.30% |
| Weighted Average Cost of Capital (WACC) | -7.15% |
| Revenue Per Employee | 294,257 |
| Profits Per Employee | -217,188 |
| Employee Count | 6 |
| Asset Turnover | 4.31 |
| Inventory Turnover | 2.74 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.00% in the last 52 weeks. The beta is -2.87, so BioRegenx's price volatility has been lower than the market average.
| Beta (5Y) | -2.87 |
| 52-Week Price Change | -63.00% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 48.41 |
| Average Volume (20 Days) | 34,004 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.16 |
Income Statement
In the last 12 months, BioRegenx had revenue of 1.77 million and -1.30 million in losses. Loss per share was -0.00.
| Revenue | 1.77M |
| Gross Profit | 1.45M |
| Operating Income | -376,140 |
| Pretax Income | -1.30M |
| Net Income | -1.30M |
| EBITDA | -300,499 |
| EBIT | -376,140 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 45,806 in cash and 2.17 million in debt, with a net cash position of -2.12 million or -0.00 per share.
| Cash & Cash Equivalents | 45,806 |
| Total Debt | 2.17M |
| Net Cash | -2.12M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -4.53M |
| Book Value Per Share | -0.00 |
| Working Capital | -3.80M |
Cash Flow
In the last 12 months, operating cash flow was 27,906 and capital expenditures -9,057, giving a free cash flow of 18,849.
| Operating Cash Flow | 27,906 |
| Capital Expenditures | -9,057 |
| Depreciation & Amortization | 75,641 |
| Net Borrowing | -6,693 |
| Free Cash Flow | 18,849 |
| FCF Per Share | 0.00 |
Margins
Gross margin is 81.90%, with operating and profit margins of -21.30% and -73.81%.
| Gross Margin | 81.90% |
| Operating Margin | -21.30% |
| Pretax Margin | -73.81% |
| Profit Margin | -73.81% |
| EBITDA Margin | -17.02% |
| EBIT Margin | -21.30% |
| FCF Margin | 1.07% |
Dividends & Yields
BioRegenx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.32% |
| Shareholder Yield | -0.32% |
| Earnings Yield | -14.50% |
| FCF Yield | 0.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioRegenx has an Altman Z-Score of -164.63 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -164.63 |
| Piotroski F-Score | 5 |